2. Search Result
Search Result
Results for "

Osteoclast formation

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

12

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0656
    Usnic acid
    1 Publications Verification

    		 Bacterial Infection Cancer
    Usnic acid, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid has excellent anticancer and antimicrobial properties. Usnic acid significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .
    Usnic acid
  • HY-N2465
    Methylsticin

    		Others Inflammation/Immunology
    Methylsticin is a kavalactone isolated from the Piper methysticum . Methylsticin exhibit osteoclast formation inhibitory activity .
    Methylsticin
  • HY-N10117
    2,3-Bis(3-indolylmethyl)indole

    		RANKL/RANK Others
    2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
    2,3-Bis(3-indolylmethyl)indole
  • HY-N0499
    Cyanidin Chloride
    3 Publications Verification

    IdB 1027

    		 RANKL/RANK Cancer
    Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .
    Cyanidin Chloride
  • HY-49069
    Anti-osteoporosis agent-7

    		Drug Derivative Others
    Anti-osteoporosis agent-7 (Compound 133) is a potential anti-osteoporosis agent showing high inhibition of osteoclast formation.
    Anti-osteoporosis agent-7
  • HY-N8215
    Achyranthoside C

    		Others Metabolic Disease
    Achyranthoside C is a saponin from Achyranthes bidentata. The derivative of Achyranthoside C has inhibitory activity on osteoclast formation .
    Achyranthoside C
  • HY-N2528
    Usnic acid sodium

    		Bacterial Infection Cancer
    Usnic acid sodium, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid sodium has excellent anticancer and antimicrobial properties. Usnic acid sodium significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .
    Usnic acid sodium
  • HY-122019
    ABD56

    		Others Others
    ABD56 is a compound that induces osteoclast apoptosis and has the activity of inhibiting osteoclast formation and inducing apoptosis. ABD56 can inhibit osteoclast formation and induce apoptosis, and its mechanism is related to the inhibition of NFκB and ERK pathways.
    ABD56
  • HY-155977
    Anti-osteoporosis agent-5

    		Others Others
    Anti-osteoporosis agent-5 (compound 189) is a potent inhibitor of the formation of osteoclasts .
    Anti-osteoporosis agent-5
  • HY-168090
    Anti-osteoporosis agent-11

    		p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-P10078
    pTH (39-84) (human)

    		Thyroid Hormone Receptor Inflammation/Immunology
    pTH (39-84) (human) is a parathyroid hormone (PTH) C-terminal fragment. pTH (39-84) (human) stimulates osteoclast formation .
    pTH (39-84) (human)
  • HY-N0499R
    Cyanidin (Chloride) (Standard)

    		RANKL/RANK Cancer
    Cyanidin (Chloride) (Standard) is the analytical standard of Cyanidin (Chloride). This product is intended for research and analytical applications. Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .
    Cyanidin (Chloride) (Standard)
  • HY-N10062
    Amakusamine

    		RANKL/RANK Others
    Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC50 value of 10.5 μM in RAW264.7 cells.
    Amakusamine
  • HY-N2465R
    Methylsticin (Standard)

    		Others Inflammation/Immunology
    Methylsticin (Standard) is the analytical standard of Methylsticin. This product is intended for research and analytical applications. Methylsticin is a kavalactone isolated from the Piper methysticum . Methylsticin exhibit osteoclast formation inhibitory activity .
    Methylsticin (Standard)
  • HY-155985
    Anti-osteoporosis agent-6

    		Others Metabolic Disease
    Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM .
    Anti-osteoporosis agent-6
  • HY-118668
    ABD-350

    		Others Others
    ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
    ABD-350
  • HY-149472
    Anti-osteoporosis agent-4

    		NF-κB PI3K Inflammation/Immunology
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .
    Anti-osteoporosis agent-4
  • HY-121282B
    Mepazine acetate

    Pecazine acetate

    		 Apoptosis MALT1 Others
    Mepazine acetate (Pecazine acetate) is a drug that has the activity to inhibit the protease activity of MALT1. Mepazine acetate is often used to study the role of MALT1 in biology. Treatment of mouse bone marrow precursor cells with mepazine acetate strongly inhibited RANK ligand (RANKL)-induced osteoclast formation. Mepazine acetate also inhibited the expression of multiple osteoclast markers such as TRAP, feline hepsin K, and calcitonin. The protective effect of mepazine acetate was not affected by MALT1 deficiency. The mechanism of action of mepazine acetate may involve MALT1-independent mechanisms, and this aspect needs to be considered in future studies .
    Mepazine acetate
  • HY-147369
    NFATc1-IN-1
    1 Publications Verification

    		 Nuclear Factor of activated T Cells (NFAT) Others
    NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .
    NFATc1-IN-1
  • HY-B1246
    Thonzonium bromide
    5 Publications Verification

    		 Bacterial Proton Pump Infection
    Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
    Thonzonium bromide
  • HY-127090
    Muramyl dipeptide
    3 Publications Verification

    MDP

    		 p38 MAPK NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist .
    Muramyl dipeptide
  • HY-130237
    Cinnamtannin B-1

    		Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1
  • HY-130237R
    Cinnamtannin B-1 (Standard)

    		Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 (Standard) is the analytical standard of Cinnamtannin B-1. This product is intended for research and analytical applications. Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1 (Standard)
  • HY-N6973
    Boldine
    1 Publications Verification

    		 RANKL/RANK Apoptosis Inflammation/Immunology Cancer
    Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research .
    Boldine
  • HY-168336
    E0924G

    		PPAR Metabolic Disease
    E0924G is an orally active activator for PPARδ with EC50 of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .
    E0924G
  • HY-B1246R
    Thonzonium bromide (Standard)

    		Bacterial Proton Pump Infection
    Thonzonium (bromide) (Standard) is the analytical standard of Thonzonium (bromide). This product is intended for research and analytical applications. Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
    Thonzonium bromide (Standard)
  • HY-112499
    Menaquinone-7
    1 Publications Verification

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 Others Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-12398
    TEI-9647
    1 Publications Verification

    		 VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-112499R
    Menaquinone-7 (Standard)

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Others Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-N7204
    4-Hydroxyderricin
    1 Publications Verification

    		 Monoamine Oxidase Dopamine β-hydroxylase Apoptosis Neurological Disease Inflammation/Immunology
    4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is an orally active, potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC50 of 3.43 μM. 4-Hydroxyderricin also mildly inhibits dopamine β (DBH)-hydroxylase activity. 4-Hydroxyderricin has antidepressant activity, anti-allergic, anti-diabetic, anti-oxidant, and antitumor effects. 4-Hydroxyderricin promotes apoptosis and cell cycle arrest through regulating PI3K/AKT/mTOR pathway in hepatocellular cells. 4-Hydroxyderricin inhibits osteoclast formation and accelerates osteoblast differentiation . 4-Hydroxyderricin is promising for research of inflammatory diseases .
    4-Hydroxyderricin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: